Exploring the Application of Vitamin D in Blood Phosphorus Control for Cats with Chronic Kidney Disease: A Case Report and Analysis
Exploring the Application of Vitamin D in Blood Phosphorus Control for Cats with Chronic Kidney Disease: A Case Report and Analysis
Vitamin D, as a fat-soluble vitamin, plays a crucial role in the physiological functions of dogs and cats. It is not only involved in calcium and phosphorus metabolism but also plays an active role in immune regulation, cell growth, and kidney protection. In recent years, more and more studies have shown that vitamin D supplementation has a positive effect on the treatment and prognosis of chronic kidney disease (CKD). This article will discuss the role of vitamin D in blood phosphorus control for cats with CKD through the treatment process of a CKD cat case.
I. Case Introduction
1.1 Case Overview
Yuyuan, a male domestic cat, 6 years old, weighing 2.1 kg. The cat was a stray cat and was adopted on September 20, 2020, and immediately came to the hospital for treatment. The main complaint: depression, poor appetite, accompanied by diarrhea and vomiting, unknown urination.
1.2 Physical Examination
The cat was in good general condition (breathing, heart rate, and temperature), but was thin and had a body condition score of 2/9. Physical examination revealed ear mites, stomatitis, and dehydration (approximately 3%-5%).
1.3 Laboratory Tests
The cat's laboratory test results showed: high creatinine and blood urea nitrogen, high blood phosphorus, and slightly low blood calcium. The diagnosis was dehydration, heart, liver function, and kidney problems. In addition, the cat had bacterial and parasitic infections and severe gastrointestinal inflammation.
II. Treatment Process
2.1 First Stage Treatment
For the cat's dehydration, gastrointestinal inflammation, and kidney disease, the following treatment regimen was used:
Fluid Therapy: Lactated Ringer's solution, cephalexin, omeprazole, and metronidazole for symptomatic treatment.
Kidney Disease Treatment: Aminorex, Renkang, activated carbon, etc.
Liver Treatment: Heparin subcutaneous injection.
2.2 Treatment Outcome
After 6 days of treatment, the cat's diarrhea stopped, dehydration improved, appetite improved, and renal diet was started. Laboratory tests showed improvement in all indicators, and the kidney and liver conditions improved. The pet owner asked for discharge and stopped the intravenous fluid therapy, and continued to take oral kidney medications until October 10. Examination showed that the condition was well controlled, kidney indicators and liver indicators were all within the normal range, and the pet's weight increased to 3.1 kg. At this time, the pet owner chose to stop treatment and only continued to feed the cat's renal diet.
2.3 Second Stage Treatment
On November 3, 2020, the pet came to the hospital for a physical examination due to other diseases, and found that blood phosphorus and blood urea nitrogen exceeded the normal range, suggesting recurrence of kidney disease. Renchangping (Chongerxiang®) was used for treatment.
2.4 Treatment Outcome
After 50 days of treatment, examination revealed that kidney-related indicators recovered, blood routine, biochemistry, and blood gas test results were basically normal, the pet was in good condition, and the weight increased to 3.8 kg. Renchangping was discontinued, and follow-up examinations were conducted in February and June 2021 due to other diseases, and it was found that all kidney indicators were normal, and the pet's weight increased to 4.6 kg. The X-ray results in March 2021 showed that the size and shape of the kidneys were basically normal.
III. Discussion
The patient presented with gastrointestinal inflammation, kidney disease, and liver disease, and after the first stage of symptomatic treatment, gastrointestinal inflammation and liver conditions improved, and kidney indicators also returned to normal. However, 23 days after discharge, blood phosphorus exceeded the normal range again, suggesting recurrence of kidney disease. Renchangping was used for renal treatment in the second stage, and after taking it for 50 days, kidney indicators recovered, and the re-examination results were normal 6 months after stopping treatment.
Based on the changes in kidney indicators such as creatinine, blood urea nitrogen, and blood phosphorus during treatment, the pet's physical condition, and X-ray examination results, the case can be comprehensively judged as CKD stage 2. At this stage, 50%-70% of nephrons are lost, and the remaining nephrons are not enough to completely excrete metabolic waste, so kidney indicators are abnormal.
According to IRIS (International Renal Interest Society) treatment guidelines, pets at this stage need to be fed a renal diet long-term and blood phosphorus levels need to be controlled. In the process of blood phosphorus control in this case, the renal treatment in the second stage was more effective, and all relevant kidney indicators returned to the normal range after treatment, and there was no recurrence within half a year of stopping treatment. The reason is mainly related to the treatment product. The first stage of treatment used Renkang, activated carbon (phosphorus binder), and Shenshuiting (amino acid-based nutritional product), while the second stage of treatment used Renchangping (phosphorus binder and vitamin D).
Phosphorus binders can effectively bind phosphorus in the intestines, preventing excessive phosphorus from being absorbed into the blood, thereby reducing blood phosphorus levels, reducing the phosphorus excretion burden on the kidneys, and helping to alleviate kidney disease. As a phosphorus binder, Renchangping is special in that it not only contains polyaminoglucose and calcium lactate, which can effectively bind phosphorus, but also specifically adds vitamin D.
First, this case was originally a stray cat with limited food sources, and it also had gastrointestinal disease and poor digestion and absorption, all of which can lead to vitamin D deficiency. In addition, the pet has kidney and liver disease, which results in insufficient conversion to active 1,25-(OH)2D3, which is very detrimental to the pet's health, so it is necessary to supplement vitamin D.
Second, vitamin D showed a special protective and restorative effect in the process of blood phosphorus control in this case, which may be achieved through multiple pathways such as inhibiting podocyte apoptosis, inhibiting excessive mesangial cell proliferation, anti-inflammatory reaction, or inhibiting RAS activation.
IV. Reflections
The treatment process of this case shows that vitamin D plays an important role in blood phosphorus control for cats with chronic kidney disease. It can not only serve as a phosphorus binder to help reduce blood phosphorus levels but also play its unique kidney protective role, helping to slow the progression of CKD.
It is recommended that more research on the application of vitamin D be conducted in the clinical treatment of cats with CKD in the future, in order to achieve better treatment outcomes for kidney disease.
Vitamin D, as a fat-soluble vitamin, plays a crucial role in the physiological functions of dogs and cats. It is not only involved in calcium and phosphorus metabolism but also plays an active role in immune regulation, cell growth, and kidney protection. In recent years, more and more studies have shown that vitamin D supplementation has a positive effect on the treatment and prognosis of chronic kidney disease (CKD). This article will discuss the role of vitamin D in blood phosphorus control for cats with CKD through the treatment process of a CKD cat case.
I. Case Introduction
1.1 Case Overview
Yuyuan, a male domestic cat, 6 years old, weighing 2.1 kg. The cat was a stray cat and was adopted on September 20, 2020, and immediately came to the hospital for treatment. The main complaint: depression, poor appetite, accompanied by diarrhea and vomiting, unknown urination.
1.2 Physical Examination
The cat was in good general condition (breathing, heart rate, and temperature), but was thin and had a body condition score of 2/9. Physical examination revealed ear mites, stomatitis, and dehydration (approximately 3%-5%).
1.3 Laboratory Tests
The cat's laboratory test results showed: high creatinine and blood urea nitrogen, high blood phosphorus, and slightly low blood calcium. The diagnosis was dehydration, heart, liver function, and kidney problems. In addition, the cat had bacterial and parasitic infections and severe gastrointestinal inflammation.
II. Treatment Process
2.1 First Stage Treatment
For the cat's dehydration, gastrointestinal inflammation, and kidney disease, the following treatment regimen was used:
Fluid Therapy: Lactated Ringer's solution, cephalexin, omeprazole, and metronidazole for symptomatic treatment.
Kidney Disease Treatment: Aminorex, Renkang, activated carbon, etc.
Liver Treatment: Heparin subcutaneous injection.
2.2 Treatment Outcome
After 6 days of treatment, the cat's diarrhea stopped, dehydration improved, appetite improved, and renal diet was started. Laboratory tests showed improvement in all indicators, and the kidney and liver conditions improved. The pet owner asked for discharge and stopped the intravenous fluid therapy, and continued to take oral kidney medications until October 10. Examination showed that the condition was well controlled, kidney indicators and liver indicators were all within the normal range, and the pet's weight increased to 3.1 kg. At this time, the pet owner chose to stop treatment and only continued to feed the cat's renal diet.
2.3 Second Stage Treatment
On November 3, 2020, the pet came to the hospital for a physical examination due to other diseases, and found that blood phosphorus and blood urea nitrogen exceeded the normal range, suggesting recurrence of kidney disease. Renchangping (Chongerxiang®) was used for treatment.
2.4 Treatment Outcome
After 50 days of treatment, examination revealed that kidney-related indicators recovered, blood routine, biochemistry, and blood gas test results were basically normal, the pet was in good condition, and the weight increased to 3.8 kg. Renchangping was discontinued, and follow-up examinations were conducted in February and June 2021 due to other diseases, and it was found that all kidney indicators were normal, and the pet's weight increased to 4.6 kg. The X-ray results in March 2021 showed that the size and shape of the kidneys were basically normal.
III. Discussion
The patient presented with gastrointestinal inflammation, kidney disease, and liver disease, and after the first stage of symptomatic treatment, gastrointestinal inflammation and liver conditions improved, and kidney indicators also returned to normal. However, 23 days after discharge, blood phosphorus exceeded the normal range again, suggesting recurrence of kidney disease. Renchangping was used for renal treatment in the second stage, and after taking it for 50 days, kidney indicators recovered, and the re-examination results were normal 6 months after stopping treatment.
Based on the changes in kidney indicators such as creatinine, blood urea nitrogen, and blood phosphorus during treatment, the pet's physical condition, and X-ray examination results, the case can be comprehensively judged as CKD stage 2. At this stage, 50%-70% of nephrons are lost, and the remaining nephrons are not enough to completely excrete metabolic waste, so kidney indicators are abnormal.
According to IRIS (International Renal Interest Society) treatment guidelines, pets at this stage need to be fed a renal diet long-term and blood phosphorus levels need to be controlled. In the process of blood phosphorus control in this case, the renal treatment in the second stage was more effective, and all relevant kidney indicators returned to the normal range after treatment, and there was no recurrence within half a year of stopping treatment. The reason is mainly related to the treatment product. The first stage of treatment used Renkang, activated carbon (phosphorus binder), and Shenshuiting (amino acid-based nutritional product), while the second stage of treatment used Renchangping (phosphorus binder and vitamin D).
Phosphorus binders can effectively bind phosphorus in the intestines, preventing excessive phosphorus from being absorbed into the blood, thereby reducing blood phosphorus levels, reducing the phosphorus excretion burden on the kidneys, and helping to alleviate kidney disease. As a phosphorus binder, Renchangping is special in that it not only contains polyaminoglucose and calcium lactate, which can effectively bind phosphorus, but also specifically adds vitamin D.
First, this case was originally a stray cat with limited food sources, and it also had gastrointestinal disease and poor digestion and absorption, all of which can lead to vitamin D deficiency. In addition, the pet has kidney and liver disease, which results in insufficient conversion to active 1,25-(OH)2D3, which is very detrimental to the pet's health, so it is necessary to supplement vitamin D.
Second, vitamin D showed a special protective and restorative effect in the process of blood phosphorus control in this case, which may be achieved through multiple pathways such as inhibiting podocyte apoptosis, inhibiting excessive mesangial cell proliferation, anti-inflammatory reaction, or inhibiting RAS activation.
IV. Reflections
The treatment process of this case shows that vitamin D plays an important role in blood phosphorus control for cats with chronic kidney disease. It can not only serve as a phosphorus binder to help reduce blood phosphorus levels but also play its unique kidney protective role, helping to slow the progression of CKD.
It is recommended that more research on the application of vitamin D be conducted in the clinical treatment of cats with CKD in the future, in order to achieve better treatment outcomes for kidney disease.
This article is original, please keep the link when forwarding:https://www.5zo.net/showinfo-4-87765-0.html